Home/Investors/The Column Group

The Column Group

Biotech Investor · 14 portfolio companies

Portfolio

14

Combined Value

$30.4B

Focus Areas

14

Top Stage

preclinical

Investment Focus

Oncology Neurodegenerative Diseases Metabolic Ophthalmology Gastroenterology Neuroscience Rare Disease Genetics & Genomics Migraine Metabolic Disorders Neurological Disorders Metabolic Diseases Metabolic Disease Infectious Disease

Portfolio Companies

Company	Stage	Valuation	Focus
REVOLUTION Medicines	Phase 2	$30.4B	Oncology
Scoop	preclinical	—	Oncology, Neurodegenerative Diseases
NGM Biopharmaceuticals	Phase 2	—	Oncology, Metabolic
Quanta Therapeutics	phase-1	—	Oncology
Accent Therapeutics	preclinical	—	Oncology
Initial Therapeutics	preclinical	—	Neuroscience, Rare Disease
Cajal Neuroscience	preclinical	—	Neuroscience, Genetics & Genomics
Kallyope	Phase 2	—	Migraine, Metabolic Disorders
Nura Bio	Pre-clinical	—	Neurological Disorders
Plexium	Pre-clinical	—	—
Surrozen	—	—	Ophthalmology
NGM Bio	phase-2	—	Metabolic Diseases, Oncology
Carmot Therapeutics	phase-2	—	Metabolic Disease, Oncology
ViralGuard	phase-1	—	Infectious Disease

Frequent Co-Investors

Lux Capital3 shared Atlas Venture2 shared RA Capital Management2 shared Two Sigma Ventures2 shared Public market investors1 shared Cormorant Asset Management1 shared DCVC Bio1 shared Boxer Capital1 shared